Efficacy of Thrice-daily versus Twice-daily Insulin Regimens on Glycohemoglobin (Hb A1c) in Type 1 Diabetes Mellitus: A Randomized Controlled Trial
- PMID: 22043371
- PMCID: PMC3191615
- DOI: 10.5001/omj.2011.03
Efficacy of Thrice-daily versus Twice-daily Insulin Regimens on Glycohemoglobin (Hb A1c) in Type 1 Diabetes Mellitus: A Randomized Controlled Trial
Abstract
Objectives: To improve glycemic control and prevent late complications, the patient and diabetes team need to adjust insulin therapy. The aim of this study is to evaluate the efficacy of thrice-daily versus twice-daily insulin regimens on HbA1c for type 1 diabetes mellitus by a randomized controlled trial in Hamedan, west of Iran.
Methods: The study included 125 patients under 19 years of age with type 1 diabetes mellitus over a 3-month period. All patients with glycohemoglobin (HbA1c) ≥8% were followed prospectively and randomized into two trial and control groups. The control group received conventional two insulin injections per day: a mixture of short-acting (regular) + intermediated acting (NPH) insulins pre-breakfast (twice daily), and the trial group was treated by an extra dose of regular insulin before lunch (three times daily). Main outcome measure was HbA1c at baseline and at the end of 3 months. The mean blood glucose level and number of hypoglycemia were recorded. All patients underwent monthly intervals follow up for assessing their home blood glucose records and insulin adjustment.
Results: Overall, 100 patients completed the study protocol. 52% were females, mean ±SD of age of 12.91 ± 3.9 years. There were no significant differences in baseline characteristics including age, gender, pubertal stage, adherence to diet, duration of disease and total daily insulin dose (p>0.05). There was a significant decrease individually in both groups in HbA1c level (p<0.05), but there was no significant difference in HbA1c reduction in patients on twice-daily insulin injections and those on thrice-daily insulin injection groups (1.12 ± 2.12 and 0.98±2.1% respectively, p>0.05).
Conclusion: Compared with twice daily insulin, a therapeutic regimen involving the addition of one dose regular insulin before lunch caused no significant change in the overall glycemic control of patients with type 1 diabetes mellitus. Our results emphasize that further efforts for near normoglycemia should be focused upon education of patients in terms of frequent outpatient visits, more blood glucose monitoring and attention to insulin adjustments.
Keywords: HbA1C; Type 1 diabetes mellitus; insulin.
Similar articles
-
Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.Rom J Intern Med. 2003;41(2):153-62. Rom J Intern Med. 2003. PMID: 15526500 Clinical Trial.
-
A Randomized Clinical Trial of Insulin Glargine and Aspart, Compared to NPH and Regular Insulin in Children with Type 1 Diabetes Mellitus.Iran J Pediatr. 2014 Apr;24(2):173-8. Iran J Pediatr. 2014. PMID: 25535536 Free PMC article.
-
Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.Diabetes Care. 2008 May;31(5):852-6. doi: 10.2337/dc07-1992. Epub 2008 Feb 11. Diabetes Care. 2008. PMID: 18268073 Clinical Trial.
-
Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.J Diabetes Complications. 2007 Jan-Feb;21(1):20-7. doi: 10.1016/j.jdiacomp.2005.11.005. J Diabetes Complications. 2007. PMID: 17189870 Clinical Trial.
-
Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes.Diabetes Ther. 2020 Mar;11(3):573-584. doi: 10.1007/s13300-019-00732-w. Epub 2019 Dec 23. Diabetes Ther. 2020. PMID: 31873857 Free PMC article. Review.
Cited by
-
Biphasic human insulin 30 thrice daily, is it reasonable?BMC Res Notes. 2020 May 24;13(1):250. doi: 10.1186/s13104-020-05090-6. BMC Res Notes. 2020. PMID: 32448382 Free PMC article. Clinical Trial.
-
Medical Diagnostic Tests: A Review of Test Anatomy, Phases, and Statistical Treatment of Data.Comput Math Methods Med. 2019 May 28;2019:1891569. doi: 10.1155/2019/1891569. eCollection 2019. Comput Math Methods Med. 2019. PMID: 31275427 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources